Last reviewed · How we verify
Moxifloxacin (Avelox)
Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria. Used for Community-acquired bacterial pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.
At a glance
| Generic name | Moxifloxacin (Avelox) |
|---|---|
| Also known as | Avelox |
| Sponsor | Connect Biopharma Australia Pty Ltd |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase; Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
As a fluoroquinolone antibiotic, moxifloxacin binds to and inhibits DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual inhibition leads to rapid bactericidal activity against a broad spectrum of aerobic and anaerobic bacteria. The drug is particularly effective against respiratory pathogens and has enhanced activity against gram-positive organisms compared to earlier fluoroquinolones.
Approved indications
- Community-acquired bacterial pneumonia
- Acute bacterial sinusitis
- Acute bacterial exacerbation of chronic bronchitis
- Uncomplicated skin and soft tissue infections
- Complicated skin and soft tissue infections
- Intra-abdominal infections
Common side effects
- Nausea
- Diarrhea
- Dizziness
- Tendinitis/tendon rupture
- QT prolongation
- Photosensitivity
- Peripheral neuropathy
Key clinical trials
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants (PHASE1)
- A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity (PHASE1)
- A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) (PHASE1)
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. (PHASE1)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moxifloxacin (Avelox) CI brief — competitive landscape report
- Moxifloxacin (Avelox) updates RSS · CI watch RSS
- Connect Biopharma Australia Pty Ltd portfolio CI